0001144204-16-131279.txt : 20161103 0001144204-16-131279.hdr.sgml : 20161103 20161103105024 ACCESSION NUMBER: 0001144204-16-131279 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20161103 ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20161103 DATE AS OF CHANGE: 20161103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ENCISION INC CENTRAL INDEX KEY: 0000930775 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 841162056 STATE OF INCORPORATION: CO FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-11789 FILM NUMBER: 161970584 BUSINESS ADDRESS: STREET 1: 6797 WINCHESTER CIRCLE CITY: BOULDER STATE: CO ZIP: 80301 BUSINESS PHONE: 3034442600 MAIL ADDRESS: STREET 1: 6797 WINCHESTER CIRCLE CITY: BOULDER STATE: CO ZIP: 80301 FORMER COMPANY: FORMER CONFORMED NAME: ELECTROSCOPE INC DATE OF NAME CHANGE: 19960502 8-K 1 v452053_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

 

Date of Report (Date of earliest event reported) November 3, 2016

 

ENCISION, INC.

(Exact name of registrant as specified in its charter)

 

Colorado 0-28604 84-1162056
(State or other jurisdiction
of incorporation)
(Commission
File Number)
(I.R.S. Employer
Identification No.)

 

6797 Winchester Circle, Boulder, Colorado 80301
(Address of principal executive offices) (Zip Code)

 

Registrant’s telephone number, including area code (303) 444-2600

 

 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

 

Item 9.01 Financial Statements and Exhibits.

 

(d)Exhibits.

 

 

99.1 Press Release issued by ENCISION, INC., November 3, 2016

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

  ENCISION, INC.
  (Registrant)
   
   
Date November 3, 2016  
/s/ Mala M Ray
  Mala M Ray
  Controller
  Principal Accounting Officer

 

 

 

EX-99.1 2 v452053_ex99-1.htm EXHIBIT 99.1

Encision Reports Second Quarter Fiscal Year 2017 Results

BOULDER, Colo., Nov. 3, 2016 /PRNewswire/ -- Encision Inc. (ECIA), a medical device company owning patented surgical technology that prevents dangerous stray electrosurgical burns in minimally invasive surgery, today announced financial results for its fiscal 2017 second quarter that ended September 30, 2016.

The Company posted quarterly net revenue of $2.15 million for a quarterly net loss of $240 thousand, or $(0.02) per share. These results compare to net revenue of $2.30 million for a net loss of $184 thousand, or $(0.02) per share, in the year-ago quarter. Gross margin on net revenue in the fiscal 2017 and 2016 six month periods was 47 percent and 51 percent respectively. Gross margin included slow moving and obsolete inventories costs of $87 thousand, or 4 percent, that were recognized in the quarter. Gross margin on net revenue was lower in the fiscal 2017 second quarter principally as a result of slow moving and obsolete inventories costs.

The Company posted six months net revenue of $4.43 million for a six months net loss of $338 thousand, or $(0.03) per share. These results compare to net revenue of $4.75 million for a net loss of $398 thousand, or $(0.04) per share, in the year-ago quarter. Gross margin on net revenue was 50 percent in the fiscal 2017 and 2016 six months.

Encision continues to fine tune our operations as we roll out new products that promise to enhance market adoption of AEM® Technology and drive higher top and bottom line results. We have had good success to date with our AEM EndoShield®2 and are converting existing AEM® Monitor customers and new customers with the cost effective and easy to use EndoShield2. We are also looking forward to the release of our new AEM® Burn Protection Cable that will offer new user features and will enhance revenues and profitability. All of this, combined with a new durable monitor, will make AEM® Safety adoption even more attractive for our customers and drive new levels of performance and growth. We expect to release the AEM® Burn Protection Cable and the durable monitor during our fourth fiscal quarter that ends March 31, 2017.

Encision Inc. designs and markets a portfolio of high performance surgical instrumentation that delivers advances in patient safety with AEM technology, surgical performance, and value to hospitals across a broad range of minimally invasive surgical procedures. Based in Boulder, CO, the company pioneered the development and deployment of Active Electrode Monitoring, AEM technology, to eliminate dangerous stray energy burns during minimally invasive procedures.

In accordance with the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, the Company notes that statements in this press release and elsewhere that look forward in time, which include everything other than historical information, involve risks and uncertainties that may cause actual results to differ materially from those indicated by the forward-looking statements. Factors that could cause the Company's actual results to differ materially include, among others, its ability to develop new or enhanced products and have such products accepted in the market, its ability to increase net sales through the Company's distribution channels, its ability to compete successfully against other manufacturers of surgical instruments, insufficient quantity of new account conversions, insufficient cash to fund operations, delay in developing new products and receiving FDA approval for such new products and other factors discussed in the Company's filings with the Securities and Exchange Commission. Readers are encouraged to review the risk factors and other disclosures appearing in the Company's Annual Report on Form 10-K for the year ended March 31, 2016 and subsequent filings with the Securities and Exchange Commission. We do not undertake any obligation to update publicly any forward-looking statements, whether as a result of the receipt of new information, future events, or otherwise.

CONTACT: Mala Ray, Encision Inc., 303-444-2600, mray@encision.com

Encision Inc.

Condensed Statements of Operations

(Amounts in thousands, except per share information)

(Unaudited)




Three Months Ended

Six Months Ended



September 30,
2016


  September 30,
2015


September 30,
2016


September 30,
2015


Net revenue


$2,151


$2,300


$4,428


$4,755


Cost of revenue


1,142


1,120


2,229


2,401


Gross profit


1,009


1,180


2,199


2,354


Operating expenses:










    Sales and marketing


614


630


1,244


1,326


    General and administrative


360


366


704


733


    Research and development


279


306


580


590


        Total operating expenses


1,253


1,302


2,528


2,649


Operating loss


(244)


(122)


(329)


(295)


Interest and other expense, net


4


(62)


(9)


(103)


Loss before provision for income taxes


(240)


(184)


(338)


(398)


Provision for income taxes


––


––


––


––


Net loss


$ (240)


$  (184)


$ (338)


$   (398)


Net loss per share—basic and diluted


$(0.02)


$ (0.02)


$(0.03)


$  (0.04)


Weighted average number of shares—basic and diluted


 

10,673


 

10,673


 

10,673


 

10,673


Encision Inc.

Condensed Balance Sheets

(Amounts in thousands)

(Unaudited)






September 30,
2016


March 31, 
2016

ASSETS





Cash and cash equivalents


$   32


$   293

Restricted cash


25


25

Accounts receivable, net


965


840

Inventories, net


1,458


1,730

Prepaid expenses


117


92

    Total current assets


2,597


2,980

Equipment, net


516


561

Patents, net


261


253

Other assets


16


16

    Total assets


$ 3,390


$ 3,810

LIABILITIES AND SHAREHOLDERS' EQUITY





Accounts payable


289


356

Accrued compensation


248


246

Other accrued liabilities


241


258

Line of credit


368


387

Deferred rent


30


30

    Total current liabilities


1,176


1,277

Deferred rent


56


71

    Total liabilities


1,232


1,348

Common stock and additional paid-in capital


23,717


23,682

Accumulated (deficit)


(21,559)


(21,220)

    Total shareholders' equity


2,158


2,462

    Total liabilities and shareholders' equity


$ 3,390


$ 3,810